We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

654 hedge funds and large institutions have $12.1B invested in State Street SPDR S&P Biotech ETF in 2020 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 233 increasing their positions, 170 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 33

55% more funds holding in top 10

Funds holding in top 10: 1117 (+6)

37% more repeat investments, than reductions

Existing positions increased: 233 | Existing positions reduced: 170

35% more capital invested

Capital invested by funds: $8.96B → $12.1B (+$3.1B)

18% more funds holding

Funds holding: 554654 (+100)

5.19% more ownership

Funds ownership: 171.15%176.34% (+5.2%)

80% less call options, than puts

Call options by funds: $883M | Put options by funds: $4.34B

Holders
654
Holders Change
+100
Holders Change %
+18.05%
% of All Funds
11.57%
Holding in Top 10
17
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+54.55%
% of All Funds
0.3%
New
138
Increased
233
Reduced
170
Closed
33
Calls
$883M
Puts
$4.34B
Net Calls
-$3.46B
Net Calls Change
-$1.53B
Name Holding Trade Value Shares
Change
Change in
Stake
BAAM
301
Baker Avenue Asset Management
California
$796K +$5.64K +44 +0.8%
CRCM
302
Corbett Road Capital Management
Virginia
$791K -$2.82K -22 -0.4%
Luther King Capital Management (LKCM)
303
Luther King Capital Management (LKCM)
Texas
$790K
NRS
304
Neville Rodie & Shaw
New York
$786K
KIG
305
Kessler Investment Group
Indiana
$783K +$640 +5 +0.1%
MCM
306
Maryland Capital Management
Maryland
$782K
APA
307
American Portfolios Advisors
New York
$766K +$16.4K +128 +2%
ACS
308
Archford Capital Strategies
Illinois
$756K +$142K +1,109 +28%
SW
309
SVB Wealth
Massachusetts
$752K +$191K +1,489 +39%
DAS
310
Dynamic Advisor Solutions
Arizona
$725K -$27.3K -213 -4%
CA
311
Cornerstone Advisory
Maryland
$720K +$512 +4 +0.1%
MOS
312
MGO One Seven
Ohio
$720K +$42.3K +330 +7%
RJT
313
Raymond James Trust
Florida
$716K -$199K -1,551 -23%
ECM
314
Evergreen Capital Management
Washington
$712K -$756K -5,900 -54%
FPCP
315
Fort Point Capital Partners
California
$708K -$6.92K -54 -1%
MS
316
Maven Securities
Jersey
$706K -$2.01M -15,676 -76%
AIP
317
ARS Investment Partners
New York
$701K +$231K +1,805 +57%
SWIG
318
Strategic Wealth Investment Group
Kentucky
$699K +$49.1K +383 +8%
PCFFS
319
Pacific Center for Financial Services
California
$697K +$29.1K +227 +5%
CC
320
Constitution Capital
Connecticut
$688K +$626K +4,887 New
RIA
321
Realta Investment Advisors
Delaware
$686K +$769 +6 +0.1%
AIC
322
Ameritas Investment Company
Nebraska
$686K +$124K +970 +25%
NEPWA
323
New England Private Wealth Advisors
Massachusetts
$670K
OCM
324
Orser Capital Management
Texas
$668K +$233K +1,820 +62%
CG
325
Colony Group
Massachusetts
$659K -$64.6K -504 -10%

XBI Hedge Fund Activity: Q4 2020 in Review

654 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2020, worth a combined $12.1B — up 35% from $8.96B a quarter earlier.

Buyers outnumbered sellers: 138 funds opened new XBI positions and 33 closed out — a net gain of 105 holders — while 233 added to existing stakes and 170 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $1.54B. The largest seller was JP Morgan Chase, cutting an estimated $1.23B.

  • 654 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2020, up from 554 in Q3 2020.
  • Funds reported $12.1B of State Street SPDR S&P Biotech ETF stock for Q4 2020, up 35% quarter-over-quarter.
  • 138 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2020 and 33 closed out, a net change of +105 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q4 2020 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.54B added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q4 2020 was JP Morgan Chase, an estimated $1.23B sold.

Based on aggregated 13F filings for Q4 2020.